Skip to Main Content
U.S. flag

An official website of the United States government

You are here:
Contact Us

Property Details for Midland Pharmaceuticals


On this page:


Legal Notices

Profile Information

Private
238269
1121 Douglas Avenue KANSAS CITY, KS 66103
28.9
39.0656095 / -94.6386166
3
Klein, Susan
Klein.Susan@epa.gov
913-551-7786


Top of Page

Property Location



Top of Page

Property Progress


Top of Page

CAs Associated with this Property

CA NameCA #StateTypeAnnouncement Year
City of Kansas City MissouriBF97741601MOAssessment2013


Top of Page

Assessment Activities at this Property

ActivityEPA FundingStart DateCompletion DateCAAccomplishment Counted?Counted When?
Phase I Environmental Assessment$6,199.0005/31/201806/26/2018City of Kansas City MissouriYFY19
Supplemental Assessment$19,062.0008/03/201810/04/2018City of Kansas City MissouriN


Is Cleanup Necessary? Unknown
EPA Assessment Funding: $25,261.00
Leveraged Funding:
Total Funding: $25,261.00


Top of Page

Climate Adaption and Mitigation - Planning or Assessment

There is no data for Climate Adaption and Mitigation - Planning or Assessment.


Top of Page

Contaminants and Media


Building Materials
NOT Cleaned up


Top of Page

Cleanup Activities

There are no current cleanup activities.


Cleanup/Treatment Implemented:
Cleanup/Treatement Categories:
Addl Cleanup/Treatment info:
Address of Data Source:
Total ACRES Cleaned Up: 28.9
Number of Cleanup Jobs Leveraged:
EPA Cleanup Funding:
Leveraged Funding:
Cost Share Funding:
Total Funding:


Top of Page

Climate Adaption and Mitigation - Demolition or Cleanup

There is no data for Climate Adaption and Mitigation - Demolition or Cleanup.


Top of Page

Institutional and Engineering Controls

U


Top of Page

Redevelopment and Other Leveraged Accomplishments

There are no current redevelopment activities.


Number of Redevelopment Jobs Leveraged:
Actual Acreage of Greenspace Created:
Leveraged Funding:


Top of Page

Climate Adaption and Mitigation - Redevelopment

There is no data for Climate Adaption and Mitigation – Redevelopment


Top of Page

Additional Property Attributes

The Phase I Environmental Site Assessment (ESA) completed in June 2018 indicated that hazardous wastes are present in the hazardous waste storage building, with evidence of a chemical spill entering a floor drain in the building. The presence of chemical spills, containers in poor condition, and the floor drain with an unknown terminus posed Recognized Environmental Conditions (REC) to the subject property. Additionally, the presence of mold-impacted materials, lead-based paint (LBP) and asbestos-containing building materials (ACBM) are likely present in the buildings. Recommendations included a hazardous materials survey of the buildings, user determination of the terminus of the drain discharge, full survey for LBP and ACBM, and survey for mold-impacted materials. The Hazardous Materials Survey (HMS) was conducted between 8/27/18 and 9/17/18. Of the approximate 20 buildings surveyed, ACM was identified in 14 buildings (i.e., floor tile, mastic, caulk, roof paper, skim coat, window glaze, roof membrane, roof material, roof flashing, roof shingle, cove base, linoleum, ceiling material, drywall, thermal system insulation, and sink undercoat) and LBP identified in ten buildings. No evidence of mold-impacted materials was observed during the HMS.The Unified Government is working to assist an undisclosed party in the purchase of the former pharmaceuticals campus for commercial redevelopment as a records management and storage facility. The redevelopment of this site is planned in three phases. The initial phase is scheduled to start in late Summer of 2018 and consists of a site cleanup for the entire outside area of the complex. Funding for the initial phase is expected to come from private lending, retained earnings investment from the purchaser�s company, and private equity. The estimated value of the project is $1.8 million.

Former Use: The subject property is located in a primarily residential section of Kansas City, Kansas, and includes one parcel of land with 19 vacant buildings. Some of the buildings are interconnected and have been enlarged with multiple additions over the years. According to an Environmental Site Assessment Summary Report prepared on December 29, 2003, the subject property was first used as a family farm and veterinary practice in the 1920s. The site was developed beginning in the 1920s as a veterinary medicine/research facility. From the 1930s to present, the site was occupied by Jensen Salisbury Laboratories; Serum Manufacturing; Coopers Animal Health; Coopers Pitman-Moor; Malinckrodt Veterinary, Inc., Wellcome 103S380009 5 Laboratories; and York Pharmaceuticals (EAE 2003). According to historical documentation, the subject property hosted Midland from 2004 to 2008, and has been vacant since.
Commercial (28.9)
Hazardous


Top of Page

Release 3.0.2